Literature DB >> 29753187

DSM-5 intermittent explosive disorder: Relationship with Disruptive Mood Dysregulation Disorder.

Emil F Coccaro1.   

Abstract

OBJECTIVE: This study was designed to estimate how many adults with DSM-5 Intermittent Explosive Disorder (IED) would also meet diagnostic criteria for Disruptive Mood Dysregulation Disorder (DMDD). This was done by examining how many individuals with IED would meet the DMDD criterion of being persistently angry in between impulsive aggressive outbursts.
METHODS: The first one-hundred study participants diagnosed with DSM-5 IED in our clinical research program were included in this study. Two questions were added to the IED module from the Structured Clinical Interview for DSM-5 Disorders (SCID) inquiring about the duration of anger in between impulsive aggressive outbursts in IED study participants. Data regarding aggression, impulsivity, anger expression, and related dysphoric variables were also collected.
RESULTS: The proportion of time spent as angry in between impulsive aggressive outbursts was <50% of the time (~35%) for the vast majority (92%) of study participants with DSM-5 IED. Despite this, persistently-angry (i.e., angry >50% time in between outbursts) IED study participants displayed no differences from not-persistently-angry IED study participants in dysphoric and aggression/impulsivity related variables.
CONCLUSIONS: These data indicate that inter-outburst anger in those with IED is relatively brief and that such individuals do not generally display the kind of persistent anger that is a diagnostic feature of DMDD.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 29753187     DOI: 10.1016/j.comppsych.2018.04.011

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  1 in total

1.  Comorbidity of disruptive behavior disorders and intermittent explosive disorder.

Authors:  Karam Radwan; Emil F Coccaro
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2020-05-28       Impact factor: 3.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.